These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 4038580)

  • 41. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cefsulodin and ceftazidime, two antipseudomonal cephalosporins.
    Smith BR
    Clin Pharm; 1984; 3(4):373-85. PubMed ID: 6380902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. UTIs and two new antibiotics in the elderly.
    Jones SR; Kimbrough R
    Geriatrics; 1988 Jul; 43(7):49-52, 55-8. PubMed ID: 3290058
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.
    Feris J; Moledina N; Rodriguez WJ; Khan WN; Puig J; Wiedermann BL; Ahmad S
    Chemotherapy; 1989; 35 Suppl 1():31-8. PubMed ID: 2731448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Chemotherapy of refractory infections--selection and application of anti-microbial agents].
    Nihon Rinsho; 1988 Jul; 46 Suppl():345-89. PubMed ID: 3271255
    [No Abstract]   [Full Text] [Related]  

  • 48. [Current therapeutic indications of aminoglycosides].
    Modai J
    Presse Med; 1984 Apr; 13(16):991-5. PubMed ID: 6232528
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli.
    Rodríguez JR; Ramírez-Ronda CH; Nevárez M
    Antimicrob Agents Chemother; 1985 Feb; 27(2):246-51. PubMed ID: 4039118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of aztreonam in lower respiratory tract infections.
    Cook JL
    Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of cefuroxime in infective pluriorgan pathology. Observations on 60 cases].
    Failla S; Longo D; Fichera M
    Clin Ter; 1984 Nov; 111(3):227-42. PubMed ID: 6240364
    [No Abstract]   [Full Text] [Related]  

  • 53. Therapeutic considerations in using combinations of newer beta-lactam antibiotics.
    Barriere SL
    Clin Pharm; 1986 Jan; 5(1):24-33. PubMed ID: 3512153
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial combinations in the therapy of infections due to gram-negative bacilli.
    Allan JD; Moellering RC
    Am J Med; 1985 Feb; 78(2A):65-76. PubMed ID: 3918445
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections.
    Swabb EA; Jenkins SA; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S772-7. PubMed ID: 3909336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
    Klastersky J
    Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside.
    DeJace P; Klastersky J
    Am J Med; 1986 Jun; 80(6B):29-38. PubMed ID: 3524218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aztreonam: review of the clinical experience and potential uses in pediatrics.
    Lebel MH; McCracken GH
    Pediatr Infect Dis J; 1988 May; 7(5):331-9. PubMed ID: 3288947
    [No Abstract]   [Full Text] [Related]  

  • 59. [Multicenter study of cefoperazone in Austria].
    Forenbacher HH
    Wien Med Wochenschr; 1985 Mar; 135(5):123-6. PubMed ID: 3993050
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunocompromised animal models for the study of antibiotic combinations.
    Calandra T; Glauser MP
    Am J Med; 1986 May; 80(5C):45-52. PubMed ID: 3087166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.